Insmed Statistics
Total Valuation
Insmed has a market cap or net worth of $12.19 billion. The enterprise value is $12.40 billion.
Important Dates
The next estimated earnings date is Thursday, May 8, 2025, before market open.
Earnings Date | May 8, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Insmed has 181.00 million shares outstanding. The number of shares has increased by 16.81% in one year.
Current Share Class | 181.00M |
Shares Outstanding | 181.00M |
Shares Change (YoY) | +16.81% |
Shares Change (QoQ) | +3.05% |
Owned by Insiders (%) | 0.88% |
Owned by Institutions (%) | 100.74% |
Float | 166.41M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 31.20 |
Forward PS | 26.22 |
PB Ratio | 43.48 |
P/TBV Ratio | 105.66 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
EV / Earnings | n/a |
EV / Sales | 34.09 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.45, with a Debt / Equity ratio of 4.59.
Current Ratio | 5.45 |
Quick Ratio | 4.99 |
Debt / Equity | 4.59 |
Debt / EBITDA | n/a |
Debt / FCF | n/a |
Interest Coverage | -9.24 |
Financial Efficiency
Return on Equity (ROE) | n/a |
Return on Assets (ROA) | -29.31% |
Return on Invested Capital (ROIC) | -37.49% |
Return on Capital Employed (ROCE) | -45.53% |
Revenue Per Employee | $286,158 |
Profits Per Employee | -$718,939 |
Employee Count | 1,271 |
Asset Turnover | 0.22 |
Inventory Turnover | 0.94 |
Taxes
In the past 12 months, Insmed has paid $3.71 million in taxes.
Income Tax | 3.71M |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +140.60% in the last 52 weeks. The beta is 1.07, so Insmed's price volatility has been similar to the market average.
Beta (5Y) | 1.07 |
52-Week Price Change | +140.60% |
50-Day Moving Average | 77.53 |
200-Day Moving Average | 73.75 |
Relative Strength Index (RSI) | 28.94 |
Average Volume (20 Days) | 1,647,992 |
Short Selling Information
The latest short interest is 14.47 million, so 7.99% of the outstanding shares have been sold short.
Short Interest | 14.47M |
Short Previous Month | 14.62M |
Short % of Shares Out | 7.99% |
Short % of Float | 8.69% |
Short Ratio (days to cover) | 7.29 |
Income Statement
In the last 12 months, Insmed had revenue of $363.71 million and -$913.77 million in losses. Loss per share was -$5.57.
Revenue | 363.71M |
Gross Profit | 277.97M |
Operating Income | -786.57M |
Pretax Income | -799.73M |
Net Income | -913.77M |
EBITDA | -777.70M |
EBIT | -786.57M |
Loss Per Share | -$5.57 |
Full Income Statement Balance Sheet
The company has $1.43 billion in cash and $1.31 billion in debt, giving a net cash position of $123.88 million or $0.68 per share.
Cash & Cash Equivalents | 1.43B |
Total Debt | 1.31B |
Net Cash | 123.88M |
Net Cash Per Share | $0.68 |
Equity (Book Value) | 285.38M |
Book Value Per Share | 1.59 |
Working Capital | 1.32B |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$683.88 million and capital expenditures -$21.92 million, giving a free cash flow of -$705.81 million.
Operating Cash Flow | -683.88M |
Capital Expenditures | -21.92M |
Free Cash Flow | -705.81M |
FCF Per Share | -$3.90 |
Full Cash Flow Statement Margins
Gross margin is 76.43%, with operating and profit margins of -216.26% and -251.24%.
Gross Margin | 76.43% |
Operating Margin | -216.26% |
Pretax Margin | -250.22% |
Profit Margin | -251.24% |
EBITDA Margin | -213.82% |
EBIT Margin | -216.26% |
FCF Margin | n/a |
Dividends & Yields
Insmed does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -16.81% |
Shareholder Yield | -16.81% |
Earnings Yield | -7.30% |
FCF Yield | -5.64% |
Dividend Details Analyst Forecast
The average price target for Insmed is $95.36, which is 41.57% higher than the current price. The consensus rating is "Strong Buy".
Price Target | $95.36 |
Price Target Difference | 41.57% |
Analyst Consensus | Strong Buy |
Analyst Count | 16 |
Revenue Growth Forecast (5Y) | 66.59% |
EPS Growth Forecast (5Y) | n/a |
Stock Forecasts Stock Splits
The last stock split was on March 3, 2011. It was a reverse split with a ratio of 0.1:1.
Last Split Date | Mar 3, 2011 |
Split Type | Reverse |
Split Ratio | 0.1:1 |
Scores
Insmed has an Altman Z-Score of -0.28 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | -0.28 |
Piotroski F-Score | 4 |